Wall Street Zen Upgrades Lyell Immunopharma (NASDAQ:LYEL) to Hold

Lyell Immunopharma (NASDAQ:LYEL) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

Several other equities research analysts have also commented on LYEL. Citigroup reiterated a “market outperform” rating on shares of Lyell Immunopharma in a research note on Friday, August 14th. Stifel Nicolaus began coverage on Lyell Immunopharma in a research note on Thursday, August 6th. They issued a “buy” rating and a $36.00 target price on the stock. Citizens Jmp reaffirmed a “market outperform” rating and issued a $34.00 target price on shares of Lyell Immunopharma in a report on Monday, June 15th. B. Riley Financial began coverage on Lyell Immunopharma in a research report on Wednesday, July 22nd. They set a “buy” rating and a $44.00 price target for the company. Finally, Royal Bank Of Canada set a $34.00 price target on Lyell Immunopharma in a report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $40.86.

Lyell Immunopharma Price Performance

NASDAQ LYEL opened at $9.85 on Friday. Lyell Immunopharma has a 1 year low of $9.81 and a 1 year high of $45.00. The firm has a market cap of $241.32 million, a price-to-earnings ratio of -0.77 and a beta of -0.04. The company has a fifty day moving average price of $13.29 and a 200-day moving average price of $16.33.

Lyell Immunopharma (NASDAQ:LYEL) last announced its earnings results on Thursday, August 6th. The company reported ($1.92) EPS for the quarter, beating the consensus estimate of ($1.94) by $0.02. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. The company had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.00 million. On average, research analysts anticipate that Lyell Immunopharma will post -7.2 EPS for the current fiscal year.

Institutional Trading of Lyell Immunopharma

Several hedge funds have recently added to or reduced their stakes in LYEL. BBR Partners LLC purchased a new position in Lyell Immunopharma in the fourth quarter valued at about $210,000. Bank of New York Mellon Corp purchased a new position in Lyell Immunopharma in the second quarter valued at approximately $347,000. Walleye Capital LLC bought a new position in Lyell Immunopharma during the first quarter valued at $445,000. Squarepoint Ops LLC grew its holdings in Lyell Immunopharma by 119.4% during the second quarter. Squarepoint Ops LLC now owns 42,322 shares of the company’s stock valued at $595,000 after purchasing an additional 23,028 shares during the period. Finally, Bank of America Corp DE increased its position in Lyell Immunopharma by 314.2% in the first quarter. Bank of America Corp DE now owns 33,321 shares of the company’s stock worth $668,000 after buying an additional 25,276 shares during the last quarter. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing T-cell therapies for patients with cancer. The company’s research is aimed at addressing challenges that can limit the effectiveness of cellular immunotherapies, including T-cell exhaustion, inadequate persistence and difficulty penetrating solid tumors.

Lyell uses its cellular reprogramming and genetic engineering technologies to develop therapeutic T cells, including chimeric antigen receptor (CAR) T-cell candidates.